Cargando…

The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors

BACKGROUND: Mucins are heavily O-glycosylated proteins where the glycosylation has been shown to play an important role in cancer. Normal epithelial ovarian cells do not express secreted mucins, but their abnormal expression has previously been described in epithelial ovarian cancer and may relate t...

Descripción completa

Detalles Bibliográficos
Autores principales: Vitiazeva, Varvara, Kattla, Jayesh J., Flowers, Sarah A., Lindén, Sara K., Premaratne, Pushpa, Weijdegård, Birgitta, Sundfeldt, Karin, Karlsson, Niclas G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468167/
https://www.ncbi.nlm.nih.gov/pubmed/26075384
http://dx.doi.org/10.1371/journal.pone.0130197
_version_ 1782376454398410752
author Vitiazeva, Varvara
Kattla, Jayesh J.
Flowers, Sarah A.
Lindén, Sara K.
Premaratne, Pushpa
Weijdegård, Birgitta
Sundfeldt, Karin
Karlsson, Niclas G.
author_facet Vitiazeva, Varvara
Kattla, Jayesh J.
Flowers, Sarah A.
Lindén, Sara K.
Premaratne, Pushpa
Weijdegård, Birgitta
Sundfeldt, Karin
Karlsson, Niclas G.
author_sort Vitiazeva, Varvara
collection PubMed
description BACKGROUND: Mucins are heavily O-glycosylated proteins where the glycosylation has been shown to play an important role in cancer. Normal epithelial ovarian cells do not express secreted mucins, but their abnormal expression has previously been described in epithelial ovarian cancer and may relate to tumor formation and progression. The cyst fluids were shown to be a rich source for acidic glycoproteins. The study of these proteins can potentially lead to the identification of more effective biomarkers for ovarian cancer. METHODS: In this study, we analyzed the expression of the MUC5AC and the O-glycosylation of acidic glycoproteins secreted into ovarian cyst fluids. The samples were obtained from patients with serous and mucinous ovarian tumors of different stages (benign, borderline, malignant) and grades. The O-linked oligosaccharides were released and analyzed by negative-ion graphitized carbon Liquid Chromatography (LC) coupled to Electrospray Ionization tandem Mass Spectrometry (ESI-MS(n)). The LC-ESI-MS(n) of the oligosaccharides from ovarian cyst fluids displayed differences in expression of fucose containing structures such as blood group ABO antigens and Lewis-type epitopes. RESULTS: The obtained data showed that serous and mucinous benign adenomas, mucinous low malignant potential carcinomas (LMPs, borderline) and mucinous low-grade carcinomas have a high level of blood groups and Lewis type epitopes. In contrast, this type of fucosylated structures were low abundant in the high-grade mucinous carcinomas or in serous carcinomas. In addition, the ovarian tumors that showed a high level of expression of blood group antigens also revealed a strong reactivity towards the MUC5AC antibody. To visualize the differences between serous and mucinous ovarian tumors based on the O-glycosylation, a hierarchical cluster analysis was performed using mass spectrometry average compositions (MSAC). CONCLUSION: Mucinous benign and LMPs along with mucinous low-grade carcinomas appear to be different from serous and high-grade mucinous carcinomas based on their O-glycan profiles.
format Online
Article
Text
id pubmed-4468167
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44681672015-06-25 The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors Vitiazeva, Varvara Kattla, Jayesh J. Flowers, Sarah A. Lindén, Sara K. Premaratne, Pushpa Weijdegård, Birgitta Sundfeldt, Karin Karlsson, Niclas G. PLoS One Research Article BACKGROUND: Mucins are heavily O-glycosylated proteins where the glycosylation has been shown to play an important role in cancer. Normal epithelial ovarian cells do not express secreted mucins, but their abnormal expression has previously been described in epithelial ovarian cancer and may relate to tumor formation and progression. The cyst fluids were shown to be a rich source for acidic glycoproteins. The study of these proteins can potentially lead to the identification of more effective biomarkers for ovarian cancer. METHODS: In this study, we analyzed the expression of the MUC5AC and the O-glycosylation of acidic glycoproteins secreted into ovarian cyst fluids. The samples were obtained from patients with serous and mucinous ovarian tumors of different stages (benign, borderline, malignant) and grades. The O-linked oligosaccharides were released and analyzed by negative-ion graphitized carbon Liquid Chromatography (LC) coupled to Electrospray Ionization tandem Mass Spectrometry (ESI-MS(n)). The LC-ESI-MS(n) of the oligosaccharides from ovarian cyst fluids displayed differences in expression of fucose containing structures such as blood group ABO antigens and Lewis-type epitopes. RESULTS: The obtained data showed that serous and mucinous benign adenomas, mucinous low malignant potential carcinomas (LMPs, borderline) and mucinous low-grade carcinomas have a high level of blood groups and Lewis type epitopes. In contrast, this type of fucosylated structures were low abundant in the high-grade mucinous carcinomas or in serous carcinomas. In addition, the ovarian tumors that showed a high level of expression of blood group antigens also revealed a strong reactivity towards the MUC5AC antibody. To visualize the differences between serous and mucinous ovarian tumors based on the O-glycosylation, a hierarchical cluster analysis was performed using mass spectrometry average compositions (MSAC). CONCLUSION: Mucinous benign and LMPs along with mucinous low-grade carcinomas appear to be different from serous and high-grade mucinous carcinomas based on their O-glycan profiles. Public Library of Science 2015-06-15 /pmc/articles/PMC4468167/ /pubmed/26075384 http://dx.doi.org/10.1371/journal.pone.0130197 Text en © 2015 Vitiazeva et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Vitiazeva, Varvara
Kattla, Jayesh J.
Flowers, Sarah A.
Lindén, Sara K.
Premaratne, Pushpa
Weijdegård, Birgitta
Sundfeldt, Karin
Karlsson, Niclas G.
The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors
title The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors
title_full The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors
title_fullStr The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors
title_full_unstemmed The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors
title_short The O-Linked Glycome and Blood Group Antigens ABO on Mucin-Type Glycoproteins in Mucinous and Serous Epithelial Ovarian Tumors
title_sort o-linked glycome and blood group antigens abo on mucin-type glycoproteins in mucinous and serous epithelial ovarian tumors
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4468167/
https://www.ncbi.nlm.nih.gov/pubmed/26075384
http://dx.doi.org/10.1371/journal.pone.0130197
work_keys_str_mv AT vitiazevavarvara theolinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT kattlajayeshj theolinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT flowerssaraha theolinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT lindensarak theolinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT premaratnepushpa theolinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT weijdegardbirgitta theolinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT sundfeldtkarin theolinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT karlssonniclasg theolinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT vitiazevavarvara olinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT kattlajayeshj olinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT flowerssaraha olinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT lindensarak olinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT premaratnepushpa olinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT weijdegardbirgitta olinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT sundfeldtkarin olinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors
AT karlssonniclasg olinkedglycomeandbloodgroupantigensaboonmucintypeglycoproteinsinmucinousandserousepithelialovariantumors